Institutional shares held 57.7 Million
50.1K calls
55.9K puts
Total value of holdings $68.7M
$59K calls
$66K puts
Market Cap $79.3M
66,671,800 Shares Out.
Institutional ownership 86.6%
# of Institutions 112

Latest Institutional Activity in ACRS

Top Purchases

Q1 2024
Cwm, LLC Shares Held: 77 ($91.6)
Q4 2023
Millennium Management LLC Shares Held: 3.48M ($4.14M)
Q4 2023
Acadian Asset Management LLC Shares Held: 2.35M ($2.8M)
Q4 2023
Citadel Advisors LLC Shares Held: 5.39M ($6.41M)
Q4 2023
D. E. Shaw & Co., Inc. Shares Held: 1.94M ($2.31M)

Top Sells

Q4 2023
Blackstone Inc Shares Held: 13K ($15.5K)
Q4 2023
Rock Springs Capital Management LP Shares Held: 3M ($3.57M)
Q4 2023
Morgan Stanley Shares Held: 976K ($1.16M)
Q4 2023
Jpmorgan Chase & CO Shares Held: 69.6K ($82.8K)
Q4 2023
Caption Management, LLC Shares Held: 100 ($119)

About ACRS

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Insider Transactions at ACRS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
From 17 Insiders
Exercise of conversion of derivative security 242K shares
Open market or private purchase 38.7K shares
Sell / Disposition
From 7 Insiders
Payment of exercise price or tax liability 59.9K shares
Open market or private sale 18K shares

Track Institutional and Insider Activities on ACRS

Follow Aclaris Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if


Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS